Benzinga

Benzinga

Benzinga

venerdì, agosto 28

NeoGenomics Inc

NEONASDAQ
Trade with Public
Trade with Public
$18.05
-0.59-3.17%
In chiusura: Aug 28, 5:00 PM EST
$18.08
0.030.17%
Post-mercato: 4:48 PM EST
PRO
Perché si muove?:NeoGenomics shares are trading higher after the company announced that its ...
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

NeoGenomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for NeoGenomics (NEO).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

10Buy
2Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$16Upside to Avg. PT-9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 29, 2026NeedhamMike MatsonPT RaiseBuy$15→$19
Jul 24, 2026BenchmarkBruce D. JacksonPT RaiseBuy$11→$16
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Maintains Buy on NeoGenomics, Raises Price Target to $19

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.
Benzinga Newsdesk

PRO
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16

Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.
Benzinga Newsdesk

PRO
Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14

TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $13 to $14.
Benzinga Newsdesk

PRO
Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25

Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform and raises the price target from $12 to $25.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $13

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target from $12 to $13.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved